Matt Sagan, Founder, Managing Partner, and CEO of MoD Partners, as well as Co-Founder, Vice President, Chief Growth and Financial Officer at VAXiCAN, shared a post by Eric Topol, Founder and Director of Scripps Research Translational Institute at The Scripps Research Institute, on LinkedIn, adding:
“Cancer Immunotherapy Pyramid from Dr Eric Topol, MD
“The 2013 Breakthrough of the Year for Science Magazine was cancer immunotherapy, recognizing unleashing the brakes of T cells for some remarkably improved outcomes for patients with a variety of refractory cancers. 2013 was considered a turning point for cancer, with not only anti-PD-1, another checkpoint inhibitor, but also the highly encouraging results of chimeric antigen receptor (CAR) therapy with engineered T cells”
But now we’re seeing an exponential rise in new ways, clinical trial results, and a rich pipeline to prevail over cancer via immunotherapies
With Cancer Vaccines on top of the pyramid”
Quoting Eric Topol‘s post:
“It’s hard to keep up with the pace on this!
On the remarkable proliferation of cancer immunotherapies, and what’s in store.”
Other articles about Immunotherapy on OncoDaily.